Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
59 studies found for:    pasireotide
Show Display Options
Rank Status Study
1 Completed Trial to Assess the Mechanism(s) Responsible for the Effect of the Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
Condition: Hyperglycemia
Intervention: Drug: pasireotide
2 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
3 Unknown  Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: PASIREOTIDE;   Drug: PLACEBO
4 Active, not recruiting Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
5 Recruiting Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Biological: SOM230
6 Completed Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Condition: Pancreatic Cancer
Interventions: Drug: Pasireotide (SOM230);   Other: placebo
7 Active, not recruiting Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Condition: Acromegaly
Interventions: Drug: Pasireotide LAR;   Drug: Octreotide LAR
8 Recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
9 Terminated Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Condition: Gonadotroph Adenomas
Intervention: Drug: pasireotide LAR
10 Completed Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
Conditions: Hepatic Cirrhosis;   Alcoholism
Intervention: Drug: Pasireotide
11 Completed
Has Results
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide;   Drug: Octreotide
12 Recruiting Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Conditions: Castrate Resistant Prostate Cancer;   Chemotherapy Naive Prostate Cancer;   Prostate Cancer
Interventions: Drug: Pasireotide;   Drug: Everolimus;   Other: Laboratory biomarker analysis
13 Recruiting Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg;   Drug: SOM230 LAR 10 mg
14 Recruiting A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Everolimus;   Drug: Pasireotide;   Drug: Everolimus and Pasireotide
15 Active, not recruiting Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
Condition: Islet Cell Tumor
Interventions: Drug: Everolimus;   Drug: Pasireotide + Everolimus
16 Active, not recruiting Pasireotide in Prevention of GI Toxicity
Condition: Hematological Malignancies
Interventions: Drug: Pasireotide + Chemo;   Drug: Pasireotide + Total Body Irradiation
17 Terminated
Has Results
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
Condition: Cancer
Intervention: Drug: SOM230B
18 Completed
Has Results
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Condition: Carcinoid Tumors
Intervention: Drug: Pasireotide (SOM230)
19 Completed Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Conditions: Carcinoid Tumor;   Acromegaly
Intervention: Drug: Pasireotide
20 Active, not recruiting
Has Results
Monthly SOM230C for Recurrent or Progressive Meningioma
Condition: Meningioma
Intervention: Drug: SOM230C

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years